Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

KALV vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KALV Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

KALV Overall Winner 6-Pillar Tally: KALV 3 – 2 CAPR (1 Tie) Matrix Metrics: KALV 7 – 3 CAPR

As of Nov 16, 2026, KalVista Pharmaceuticals, Inc. (KALV) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). KALV carries a Unified Composite Score of 55.1/100 (HOLD) at $27.00 (25.4x Forward P/E, -57.4% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KALV vs CAPR
KALV NASDAQ Head-to-Head Winner
KalVista Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$27.00
+0.04% 1D
Market Cap $1.4B
TTM Revenue $114M
Forward P/E 25.4x
Beta / 30D Vol 0.85β · 2% Vol
Unified Composite Score
55.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (19.4% over 20 days), RSI 76
RSI-14: 76.0 · SMA20: $26.86 · SMA50: $24.01
CAPR NASDAQ
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (KALV 3 – 2 CAPR)

Columns: Metric · KALV · CAPR
1. Valuation Multiples KALV
Forward P/E 25.4x 78.7x
Trailing P/E 25.4x 78.7x
PEG Ratio N/M 0.38x
EV / Revenue 12.6x 57.8x
2. Growth & Scale KALV
Revenue Growth (YoY) +30.7% -7.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $114M $11M
Market Cap $1.4B $595.4M
3. Profitability & Quality CAPR
Gross Margin 51.1% N/A
Operating Margin -57.4% 0.0%
Net Profit Margin -118.7% 0.0%
Return on Equity (ROE) -190.2% -100.5%
4. Balance Sheet & Cash Flow KALV
Cash Generation (TTM) -$138M EBITDA -$146M
Cash Flow Margin -120.9% EBITDA Mgn N/A
Net Cash / Leverage -190.2% ROE $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 88.9% (31st %ile) 637.1% (89th %ile)
Put/Call OI Skew 26.28x (Put-Skewed) 1.57x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KALV (7) vs CAPR (3)
Institutional Metric KALV CAPR Criterion Row Edge
Market Capitalization
Scale
$1.4B $595.4M Larger Scale KALV
Trailing P/E Ratio
Valuation
25.4x 78.7x Lower Multiple KALV
Forward P/E Ratio
Valuation
25.4x 78.7x Lower Multiple KALV
Revenue Growth (YoY)
Growth
+30.7% -7.9% Higher Growth KALV
Operating Margin (TTM)
Profitability
-57.4% 0.0% Higher Margin CAPR
Net Profit Margin
Profitability
-118.7% 0.0% Higher Margin CAPR
Return on Equity (ROE)
Capital Efficiency
-190.2% -100.5% Higher ROE CAPR
52-Week Range Position
Momentum
100% ($10–$27) 15% ($3–$40) Stronger Trend KALV
Beta / 30D Volatility
Risk Regime
0.85β · 2% Vol 1.52β · 152% Vol Lower Realized Risk KALV
Unified Institutional Score
Composite Signal
55.1 / 100 (HOLD) 28.0 / 100 (SELL) Higher Composite KALV
Trailing 12M Revenue (USD)
Operating Scale
$114M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
51.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 12.6x EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$138M EBITDA (-190.2% ROE) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KALV +21.69 pp
KALV: +1.09% · CAPR: -20.6%
3M Horizon KALV +72.58 pp
KALV: +48.03% · CAPR: -24.55%
6M Horizon KALV +71.45 pp
KALV: +60.14% · CAPR: -11.31%
1Y Horizon CAPR +229.12 pp
KALV: +102.4% · CAPR: +331.52%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KALV vs CAPR. Trailing 12-month operating profitability (KALV -57.4% vs CAPR 0.0%) and valuation multiples (KALV 25.4x vs CAPR 78.7x Forward P/E) are benchmarked directly in Pillar 4 below.

KALV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$114M
Gross Margin51.1%
Op. Margin-57.4%
ROE / Fwd P/E-190.2% · 25.4x
CAPR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-100.5% · 78.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KALV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 88.9%
IV Percentile 31st %ile
Put/Call OI Skew 26.28x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact KALV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KALV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and -57.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KALV vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, KalVista Pharmaceuticals, Inc. (KALV) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). KALV carries a Unified Composite Score of 55.1/100 (HOLD) at $27.00 (25.4x Forward P/E, -57.4% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Technically, KALV sits in a Markup phase (RSI 76.0, UNCLASSIFIED options structure) and CAPR sits in a Markup phase (RSI 51.3, CONSOLIDATION options structure).

KALV leads the Growth & Scale pillar: KALV posts +30.7% YoY revenue growth and +0.0% YoY earnings growth on $114M TTM revenue (51.1% gross margin, -57.4% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, KALV generates $114M in USD-normalized revenue versus $11M for CAPR. In operating R&D and SG&A reinvestment, KALV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

KALV screens cheaper on headline valuation multiples. KALV trades at 25.4x Forward P/E, 25.4x Trailing P/E, N/M PEG, and 12.6x EV/Revenue (-120.9% EBITDA margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KALV (-190.2% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, KALV carries 88.9% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 26.28x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.85β · 2% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.